Cyclodextrin-conjugated nanocarrier for magnetically guided delivery of hydrophobic drugs
Source abstract
Abstract
A magnetic nanosystem that simultaneously implements the cyclodextrin–drug complexation power, bioadhesive property of gum arabic (GA) and inherent magnetic properties of Fe3O4 nanoparticles, has recently been reported. In this study, a magnetic nanocarrier was fabricated by conjugating 2-hydroxypropyl-cyclodextrin (HCD) onto the gum arabic modified magnetic nanoparticles (GAMNP). The analyses of transmission electron microscopy (TEM) and dynamic light scattering (DLS) revealed that the product had a mean diameter of 14.8 nm and a mean hydrodynamic diameter of 29.3 nm. This nanocarrier showed good loading efficiency for ketoprofen. In addition, the in vitro release profile of ketoprofen from HCD-GAMNP was characterized by an initial fast release followed by a delayed release phase. In view of the better biocompatibility and the combined properties like specific targeting, complexation ability with hydrophobic drugs makes the nanosystem an exciting prospect for drug delivery.
Source: openaire · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · Drug Solubulity and Delivery Systems · Advanced Drug Delivery Systems
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (22)
Show source-provided references
1. Banerjee SS, Chen DH (2007a) Magnetic nanoparticles grafted with cyclodextrin for hydrophobic drug delivery. Chem Mater 19:6345–6349. doi: 10.1021/cm702278u10.1021/cm702278u ↗
2. Banerjee SS, Chen DH (2007b) Fast removal of copper ions by gum arabic modified magnetic nano-adsorbent. J Hazard Mater 147:792–799. doi: 10.1016/j.jhazmat.2007.01.07910.1016/j.jhazmat.2007.01.079 ↗
3. Bender M, Komiyama M (1978) Cyclodextrin chemistry. Springer, Berlin10.1007/978-3-642-66842-5 ↗
4. Brewster ME, Loftsson T (2007) Cyclodextrins as pharmaceutical solubilizers. Adv Drug Deliv Rev 59:645–666. doi: 10.1016/j.addr.2007.05.01210.1016/j.addr.2007.05.012 ↗
5. Brewster ME, Mackie C et al (2007) The use of solubilizing excipients and approaches to generate toxicology vehicles for contemporary drug pipelines. In: Augustijns P, Brewster ME (eds) Solvent systems and their selection in pharmaceutics and biopharmaceutics. American Association of Pharmaceutical Scientists and Springer, New York, pp 221–26610.1007/978-0-387-69154-1_8 ↗
6. Catena GC, Bright FV (1989) Thermodynamic study on the effects of beta-cyclodextrin inclusion with anilinonaphthalenesulfonates. Anal Chem 61:905–909. doi: 10.1021/ac00183a02410.1021/ac00183a024 ↗
7. Cinteza LO, Ohulchanskyy TY et al (2006) Diacyllipid micelle-based nanocarrier for magnetically guided delivery of drugs in photodynamic therapy. Mol Pharm 3:415–423. doi: 10.1021/mp060015p10.1021/mp060015p ↗
8. Gould S, Scott RC (2005) 2-Hydroxypropyl-β-cyclodextrin (HP-β-CD): a toxicology review. Food Chem Toxicol 43:1451–1459. doi: 10.1016/j.fct.2005.03.00710.1016/j.fct.2005.03.007 ↗
9. Jeong U, Teng X et al (2007) Superparamagnetic colloids: controlled synthesis and niche applications. Adv Mater 19:33–60. doi: 10.1002/adma.20060067410.1002/adma.200600674 ↗
10. Junquera E, Aicart E (1997) Potentiometric study of the encapsulation of ketoprophen by hydroxypropyl-β- cyclodextrin. Temperature, solvent, and salt effects. J Phys Chem B 101:7163–7171. doi: 10.1021/jp963977s10.1021/jp963977s ↗
11. Jurgons R, Seliger C et al (2006) Drug loaded magnetic nanoparticles for cancer therapy. J Phys Condens Matter 18:S2893–S2902. doi: 10.1088/0953-8984/18/38/S2410.1088/0953-8984/18/38/S24 ↗
12. Kohler H, Sun C et al (2005) Methotrexate-modified superparamagnetic nanoparticles and their intracellular uptake into human cancer cells. Langmuir 21:8858–8864. doi: 10.1021/la050345110.1021/la0503451 ↗
13. Lee H, Yu MK, Park S, Moon S et al (2007) Thermally cross-linked superparamagnetic iron oxide nanoparticles: synthesis and application as a dual imaging probe for cancer in vivo. J Am Chem Soc 129:12739–12745. doi: 10.1021/ja072210i10.1021/ja072210i ↗
14. Liao MH, Chen DH (2002) Preparation and characterization of a novel magnetic nano-adsorbent. J Mater Chem 12:3654–3659. doi: 10.1039/b207158d10.1039/b207158d ↗
15. Loftsson T, Masson M (2001) Cyclodextrins in topical drug formulations: theory and practice. Int J Pharm 225:15–30. doi: 10.1016/S0378-5173(01)00761-X10.1016/S0378-5173(01)00761-X ↗
16. Nasongkla N, Bey E et al (2006) Multifunctional polymeric micelles as cancer-targeted, MRI-ultrasensitive drug delivery systems. Nano Lett 6:2427–2430. doi: 10.1021/nl061412u10.1021/nl061412u ↗
17. Nelles G, Weisser M et al (1996) J Am Chem Soc 118:5039–5046. doi: 10.1021/ja953981210.1021/ja9539812 ↗
18. Rao VM, Nerurkar M (2006) Co-solubilization of poorly soluble drugs by micellization and complexation. Int J Pharm 319:98–106. doi: 10.1016/j.ijpharm.2006.03.04210.1016/j.ijpharm.2006.03.042 ↗
19. Rozou S, Michaleas S et al (2005) Study of structural features and thermodynamic parameters, determining the chromatographic behaviour of drug–cyclodextrin complexes. J Chromatogr A 1087:86–94. doi: 10.1016/j.chroma.2005.02.03910.1016/j.chroma.2005.02.039 ↗
20. Saenger W (1984) Inclusion compounds. Academic Press, London
21. Sashiwa H, Saimoto H et al (1990) Lysozyme susceptibility of partially deacetylated chitin. Int J Biol Macromol 12:295–296. doi: 10.1016/0141-8130(90)90016-410.1016/0141-8130(90)90016-4 ↗
22. Takada K (2006) Oral formulation for gastrointestinal drug delivery. US Patent 7097851 B1